|
Synonyms: RG-7221 | RG7221 | RO5520985
Compound class:
Antibody
Comment: Vanucizumab is an investigational bi-specific monoclonal antibody, with potential anti-neoplastic activity being developed by Hoffmann-La Roche [1-2]. Vanucizumab simultaneously targets angiopoietin 2 (ANGPT2) and vascular endothelial growth factor A (VEGFA).
Annotated peptide sequences for this antibody are available from its IMGT/mAb-DB record. BLAST seuqence analysis reveals 100% matches with peptide sequences claimed in patent US8945552 and likely identify XMab1 and XMab2 as candidates for vanucizumab [1]. |
| References |
|
1. Baehner M, Imhof-Jung S, Kavlie A, Kettenberger H, Klein C, Thomas J, Schaefer W, Stubenrauch K-G, Thomas M. (2015)
Bispecific, bivalent anti-VEGF/anti-ANG-2 antibodies. Patent number: US8945552 B2. Assignee: Hoffmann-La Roche Inc.. Priority date: 26/03/2010. Publication date: 03/02/2015. |
|
2. Spiess C, Zhai Q, Carter PJ. (2015)
Alternative molecular formats and therapeutic applications for bispecific antibodies. Mol Immunol, 67 (2 Pt A): 95-106. [PMID:25637431] |
